What we have here is a coordinated phase III clinical trial.

Clearly there is some variance amongst the lot numbers with certain lots seeming to have a metastatic delivery (weaponized?).

It would be very interesting to have a biochemical analysis of vials from a "bad" lot vs. a more benign lot from each manufacturer. These lots are NOT consistent in their content...but in what way?!?

We really need to bring back public beheadings in the town square...